Tags

Type your tag names separated by a space and hit enter

High-dose sodium stibogluconate treatment of cutaneous leishmaniasis in Kenya.
Trans R Soc Trop Med Hyg. 1983; 77(5):717-21.TR

Abstract

Cutaneous leishmaniasis caused by Leishmania aethiopica usually responds poorly to conventional doses of pentavalent antimonial drugs. We treated three patients with cutaneous leishmaniasis acquired in Kenya, presumed or documented to be caused by L. aethiopica, with intravenous sodium stibogluconate, 18 to 20 mg Sb/kg body-weight twice daily for 30 days. All patients had a good response to treatment, with disappearance of parasites from skin smears and cultures after 14 to 27 days, clinical healing of the lesions, and no recurrence during a three to 18-month follow-up. Side effects of treatment were minor. We conclude that this high dose sodium stibogluconate regimen is safe and effective for treating cutaneous leishmaniasis caused by L. aethiopica in Kenya.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.

Language

eng

PubMed ID

6318408

Citation

Chulay, J D., et al. "High-dose Sodium Stibogluconate Treatment of Cutaneous Leishmaniasis in Kenya." Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 77, no. 5, 1983, pp. 717-21.
Chulay JD, Anzeze EM, Koech DK, et al. High-dose sodium stibogluconate treatment of cutaneous leishmaniasis in Kenya. Trans R Soc Trop Med Hyg. 1983;77(5):717-21.
Chulay, J. D., Anzeze, E. M., Koech, D. K., & Bryceson, A. D. (1983). High-dose sodium stibogluconate treatment of cutaneous leishmaniasis in Kenya. Transactions of the Royal Society of Tropical Medicine and Hygiene, 77(5), 717-21.
Chulay JD, et al. High-dose Sodium Stibogluconate Treatment of Cutaneous Leishmaniasis in Kenya. Trans R Soc Trop Med Hyg. 1983;77(5):717-21. PubMed PMID: 6318408.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - High-dose sodium stibogluconate treatment of cutaneous leishmaniasis in Kenya. AU - Chulay,J D, AU - Anzeze,E M, AU - Koech,D K, AU - Bryceson,A D, PY - 1983/1/1/pubmed PY - 1983/1/1/medline PY - 1983/1/1/entrez SP - 717 EP - 21 JF - Transactions of the Royal Society of Tropical Medicine and Hygiene JO - Trans R Soc Trop Med Hyg VL - 77 IS - 5 N2 - Cutaneous leishmaniasis caused by Leishmania aethiopica usually responds poorly to conventional doses of pentavalent antimonial drugs. We treated three patients with cutaneous leishmaniasis acquired in Kenya, presumed or documented to be caused by L. aethiopica, with intravenous sodium stibogluconate, 18 to 20 mg Sb/kg body-weight twice daily for 30 days. All patients had a good response to treatment, with disappearance of parasites from skin smears and cultures after 14 to 27 days, clinical healing of the lesions, and no recurrence during a three to 18-month follow-up. Side effects of treatment were minor. We conclude that this high dose sodium stibogluconate regimen is safe and effective for treating cutaneous leishmaniasis caused by L. aethiopica in Kenya. SN - 0035-9203 UR - https://www.unboundmedicine.com/medline/citation/6318408/High_dose_sodium_stibogluconate_treatment_of_cutaneous_leishmaniasis_in_Kenya_ L2 - https://academic.oup.com/trstmh/article-lookup/doi/10.1016/0035-9203(83)90213-4 DB - PRIME DP - Unbound Medicine ER -